Globus Medical, Inc. $GMED Shares Acquired by Congress Asset Management Co.

Key Points

• Congress Asset Management increased its Globus Medical stake by 6.6% in the third quarter, bringing its holdings to 361,026 shares valued at approximately $27 million. Institutional investors collectively own 95.16% of GMED.
• Globus Medical reported quarterly earnings of $1.34 per share, exceeding the $1.10 consensus estimate, while revenue rose 5.9% year over year to $789.61 million. The company guided to fiscal 2026 EPS of $4.95–$5.05.
• GMED shares opened at $76.37, below the analyst consensus price target of $99.46; analysts collectively maintain a “Moderate Buy” rating. Two directors recently sold a combined 55,000 shares.

Congress Asset Management Co. increased its position in shares of Globus Medical, Inc. (NYSE:GMED - Free Report) by 6.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 361,026 shares of the medical device company's stock after acquiring an additional 22,401 shares during the quarter. Congress Asset Management Co. owned approximately 0.27% of Globus Medical worth $27,041,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Elevation Wealth Partners LLC raised its position in shares of Globus Medical by 2,178.6% in the 2nd quarter. Elevation Wealth Partners LLC now owns 319 shares of the medical device company's stock worth $25,000 after buying an additional 305 shares during the period. Continuum Advisory LLC purchased a new stake in Globus Medical during the second quarter valued at about $25,000. Summit Securities Group LLC purchased a new stake in shares of Globus Medical during the 1st quarter worth about $48,000. Root Financial Partners LLC grew its holdings in shares of Globus Medical by 291.5% during the 1st quarter. Root Financial Partners LLC now owns 779 shares of the medical device company's stock worth $67,000 after purchasing an additional 580 shares during the period. Finally, EverSource Wealth Advisors LLC increased its position in Globus Medical by 111.5% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,199 shares of the medical device company's stock worth $103,000 after purchasing an additional 632 shares in the last quarter. 95.16% of the stock is owned by hedge funds and other institutional investors.

Globus Medical Stock Down 0.3%

Shares of NYSE:GMED opened at $76.37 on Wednesday. Globus Medical, Inc. has a 52-week low of $56.50 and a 52-week high of $101.40. The company has a 50 day moving average of $79.50 and a two-hundred day moving average of $82.00. The company has a market capitalization of $10.25 billion, a price-to-earnings ratio of 19.53, a price-to-earnings-growth ratio of 1.23 and a beta of 0.96.

Globus Medical (NYSE:GMED - Get Free Report) last announced its earnings results on Thursday, August 6th. The medical device company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.24. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. The business had revenue of $789.61 million during the quarter, compared to the consensus estimate of $782.88 million. During the same period in the prior year, the firm earned $0.86 earnings per share. The business's quarterly revenue was up 5.9% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, equities analysts anticipate that Globus Medical, Inc. will post 4.99 earnings per share for the current year.

Analyst Ratings Changes

GMED has been the topic of several research reports. Truist Financial cut their price target on shares of Globus Medical from $115.00 to $100.00 and set a "buy" rating on the stock in a report on Thursday, July 16th. Weiss Ratings reiterated a "hold (c+)" rating on shares of Globus Medical in a research note on Monday, July 13th. Stifel Nicolaus cut their target price on shares of Globus Medical from $95.00 to $80.00 and set a "hold" rating on the stock in a research note on Wednesday, July 8th. Zacks Research raised shares of Globus Medical from a "hold" rating to a "strong-buy" rating in a research note on Monday, August 10th. Finally, UBS Group began coverage on shares of Globus Medical in a report on Tuesday, July 28th. They set a "neutral" rating and a $82.00 target price on the stock. Three research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have assigned a Hold rating to the company's stock. According to MarketBeat.com, Globus Medical currently has a consensus rating of "Moderate Buy" and a consensus price target of $99.46.

Insider Transactions at Globus Medical

In other Globus Medical news, Director Stephen T. Zarrilli sold 25,000 shares of Globus Medical stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the sale, the director directly owned 25,000 shares in the company, valued at $2,176,000. The trade was a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James Tobin sold 30,000 shares of the company's stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $74.58, for a total value of $2,237,400.00. Following the completion of the transaction, the director directly owned 15,000 shares in the company, valued at approximately $1,118,700. The trade was a 66.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 18.38% of the company's stock.

About Globus Medical

Globus Medical, Inc is a medical device company that develops musculoskeletal solutions for surgeons, hospitals and ambulatory surgery centers. Its primary focus is the design, development and commercialization of products used in spinal surgery, including implants, instruments, navigation systems and robotic-assisted technologies.

The company's portfolio includes the ExcelsiusGPS robotic navigation platform, Excelsius3D imaging technology, spinal implants and systems for procedures such as deformity correction, degenerative spine treatment and minimally invasive surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.